[Angiotensin-neprilysin inhibition in ckd: does it confer a double benefit?]

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Patients with chronic kidney disease (CKD) face significant risks of disease progression to end-stage renal disease and elevated cardiovascular mortality.
• Current treatments targeting the renin-angiotensin-aldosterone system (RAAS) are standard, but novel therapeutic strategies are being investigated.

Purpose of the Study:

• To review and summarize the current evidence regarding the potential benefits of angiotensin-neprilysin inhibitors (ARNi) in patients with chronic kidney disease.
• To evaluate the efficacy of ARNi compared to traditional RAAS inhibitors in mitigating cardiovascular mortality and slowing CKD progression.

Main Methods:

• Literature review of existing clinical trials and experimental data.
• Analysis of studies investigating the effects of angiotensin-neprilysin inhibition in CKD populations.
• Synthesis of evidence from animal models and human studies.

Main Results:

• Preliminary data suggests that angiotensin-neprilysin inhibition may be more effective than RAAS inhibition in reducing cardiovascular mortality in CKD patients.
• Evidence indicates that ARNi may have a superior effect in retarding the progression of chronic kidney disease.
• Further research is ongoing to solidify these findings and establish ARNi as a primary treatment modality.

Conclusions:

• Angiotensin-neprilysin inhibitors show promise as a superior therapeutic option for managing chronic kidney disease.
• ARNi may offer significant advantages in reducing cardiovascular risk and preserving kidney function in CKD patients.
• The findings support further investigation and potential clinical adoption of ARNi for CKD management.